Research Unit, R&D Division, Kyowa Kirin Co., Ltd., 3-6-6, Otemachi Financial City Grand Cube, 1-9-2 Otemachi, Chiyoda-ku, Tokyo 100-0004, Japan.
Translational Research Unit, R&D Division, Kyowa Kirin Co., Ltd., 1188 Shimotogari, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8731, Japan.
Nucleic Acids Res. 2022 May 20;50(9):4840-4859. doi: 10.1093/nar/gkac308.
Extrahepatic delivery of small interfering RNAs (siRNAs) may have applications in the development of novel therapeutic approaches. However, reports on such approaches are limited, and the scarcity of reports concerning the systemically targeted delivery of siRNAs with effective gene silencing activity presents a challenge. We herein report for the first time the targeted delivery of CD206-targetable chemically modified mannose-siRNA (CMM-siRNA) conjugates to macrophages and dendritic cells (DCs). CMM-siRNA exhibited a strong binding ability to CD206 and selectively delivered contents to CD206-expressing macrophages and DCs. Furthermore, the conjugates demonstrated strong gene silencing ability with long-lasting effects and protein downregulation in CD206-expressing cells in vivo. These findings could broaden the use of siRNA technology, provide additional therapeutic opportunities, and establish a basis for further innovative approaches for the targeted delivery of siRNAs to not only macrophages and DCs but also other cell types.
肝外递送小干扰 RNA(siRNAs)可能在开发新型治疗方法方面具有应用。然而,此类方法的报道有限,并且关于具有有效基因沉默活性的 siRNA 的系统靶向递送的报道稀缺,这是一个挑战。我们首次报道了靶向递送至巨噬细胞和树突状细胞(DC)的 CD206 靶向化学修饰甘露糖-siRNA(CMM-siRNA)缀合物。CMM-siRNA 与 CD206 具有很强的结合能力,并选择性地将内容物递送至表达 CD206 的巨噬细胞和 DC。此外,该缀合物在体内具有强大的基因沉默能力,可长期维持并下调表达 CD206 的细胞中的蛋白质。这些发现可以拓宽 siRNA 技术的应用范围,提供更多的治疗机会,并为进一步创新的方法奠定基础,不仅可以将 siRNA 靶向递送至巨噬细胞和 DC,还可以靶向递送至其他细胞类型。